Literature DB >> 15790988

Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype.

J Yarden1, D Radojkovic, K De Boeck, M Macek, D Zemkova, V Vavrova, R Vlietinck, J-J Cassiman, H Cuppens.   

Abstract

BACKGROUND: The pulmonary phenotype in patients with cystic fibrosis (CF), even in those with the same CF transmembrane conductance regulator (CFTR) genotype, is variable and must therefore be influenced by secondary genetic factors as well as environmental factors. Possible candidate genes that modulate the CF lung phenotype may include proinflammatory cytokines. One such protein is tumour necrosis factor alpha (TNFalpha), a member of the immune system.
METHODS: Three polymorphic loci in the promoter (-851c/t, -308g/a, -238g/a) and one polymorphic locus in intron 1 (+691g ins/del) of the TNFalpha gene were typed by a single nucleotide primer extension assay in CF patients and healthy controls. Spirometric data and first age of infection with Pseudomonas aeruginosa were collected retrospectively from patients' medical records.
RESULTS: An association was found between the TNFalpha +691g ins/del polymorphic locus and severity of CF lung disease. Patients heterozygous for +691g ins and +691g del were more likely to have better pulmonary function (mean (SD) forced expiratory volume in 1 second (FEV1) 79.7 (12.8)% predicted) than patients homozygous for +691g ins (mean (SD) FEV1 67.5 (23.0)% predicted; p = 0.008, mean difference 12.2%, 95% CI 3.5 to 21.0). Also, patients heterozygous for +691g ins and +691g del were more likely to have an older first age of infection with P aeruginosa (mean (SD) 11.4 (6.0) years) than patients homozygous for +691g ins (mean (SD) 8.3 (4.6) years; p = 0.018, mean difference 3.1 years, 95% CI 0.5 to 5.6). An association was also found with the -851c/t polymorphic locus. In the group of patients with more severe FEV1% predicted, a higher proportion of patients were homozygous for the -851c allele than in the other group of patients (p = 0.04, likelihood ratio chi2, odds ratio = 2.4).
CONCLUSION: TNFalpha polymorphisms are associated with the severity of CF lung disease in Czech and Belgian patients with CF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790988      PMCID: PMC1747362          DOI: 10.1136/thx.2004.025262

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  30 in total

Review 1.  The gender gap in cystic fibrosis survival.

Authors:  P B Davis
Journal:  J Gend Specif Med       Date:  1999 Mar-Apr

2.  Polymorphisms in the mannose binding lectin gene affect the cystic fibrosis pulmonary phenotype.

Authors:  J Yarden; D Radojkovic; K De Boeck; M Macek; D Zemkova; V Vavrova; R Vlietinck; J-J Cassiman; H Cuppens
Journal:  J Med Genet       Date:  2004-08       Impact factor: 6.318

3.  Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease.

Authors:  M A Higham; N B Pride; A Alikhan; N W Morrell
Journal:  Eur Respir J       Date:  2000-02       Impact factor: 16.671

4.  Association between two tumour necrosis factor intronic polymorphisms and HLA alleles.

Authors:  A S Low; I Azmy; N Sharaf; C Cannings; A G Wilson
Journal:  Eur J Immunogenet       Date:  2002-02

5.  Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex.

Authors:  T Spies; C C Morton; S A Nedospasov; W Fiers; D Pious; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

6.  Changes in the normal maximal expiratory flow-volume curve with growth and aging.

Authors:  R J Knudson; M D Lebowitz; C J Holberg; B Burrows
Journal:  Am Rev Respir Dis       Date:  1983-06

Review 7.  Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis.

Authors:  Michael W Konstan; Pamela B Davis
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

Review 8.  Genetic risk factors of chronic obstructive pulmonary disease.

Authors:  Ladina Joos; Peter D Paré; Andrew J Sandford
Journal:  Swiss Med Wkly       Date:  2002-01-26       Impact factor: 2.193

9.  Influence of TNFalpha gene polymorphisms on TNFalpha production and disease.

Authors:  A H Hajeer; I V Hutchinson
Journal:  Hum Immunol       Date:  2001-11       Impact factor: 2.850

Review 10.  Cystic fibrosis.

Authors:  Felix Ratjen; Gerd Döring
Journal:  Lancet       Date:  2003-02-22       Impact factor: 79.321

View more
  14 in total

1.  TNF-alpha polymorphisms as a potential modifier gene in the cystic fibrosis.

Authors:  Cyntia Aac Coutinho; Fernando Al Marson; Aline Rb Marcelino; Luciana C Bonadia; Marcelo P Carlin; Antonio F Ribeiro; Jose D Ribeiro; Carmen S Bertuzzo
Journal:  Int J Mol Epidemiol Genet       Date:  2014-05-29

Review 2.  Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

Authors:  Rainer Büscher; Hartmut Grasemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-11       Impact factor: 3.000

3.  Variants in mannose-binding lectin and tumour necrosis factor alpha affect survival in cystic fibrosis.

Authors:  Kitti Buranawuti; Michael P Boyle; Suzanne Cheng; Lori L Steiner; Kathryn McDougal; M Daniele Fallin; Christian Merlo; Pamela L Zeitlin; Beryl J Rosenstein; Peter J Mogayzel; Xinjing Wang; Garry R Cutting
Journal:  J Med Genet       Date:  2006-12-11       Impact factor: 6.318

Review 4.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

5.  Comparative analysis of common CFTR polymorphisms poly-T, TG-repeats and M470V in a healthy Chinese population.

Authors:  Qin Huang; Wei Ding; Mu-Xin Wei
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

Review 6.  Cystic fibrosis.

Authors:  Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush
Journal:  Nat Rev Dis Primers       Date:  2015-05-14       Impact factor: 52.329

7.  Stabilization of lung function and clinical symptoms in a patient with cystic fibrosis (CF) after institution of infliximab: a monoclonal antibody that binds tumor necrosis factor alpha.

Authors:  Brian Casserly; Walter Donat
Journal:  Lung       Date:  2009-02-27       Impact factor: 2.584

8.  Prostaglandin-endoperoxide synthase genes COX1 and COX2 - novel modifiers of disease severity in cystic fibrosis patients.

Authors:  K Czerska; A Sobczynska-Tomaszewska; D Sands; A Nowakowska; D Bak; K Wertheim; J Poznanski; J Zielenski; A Norek; J Bal
Journal:  J Appl Genet       Date:  2010       Impact factor: 2.653

9.  TNF gene polymorphisms in cystic fibrosis patients: contribution to the disease progression.

Authors:  Galina Shmarina; Alexander Pukhalsky; Nika Petrova; Ekaterina Zakharova; Lucine Avakian; Nikolai Kapranov; Vladimir Alioshkin
Journal:  J Transl Med       Date:  2013-01-23       Impact factor: 5.531

10.  Genetic influences on cystic fibrosis lung disease severity.

Authors:  Colleen A Weiler; Mitchell L Drumm
Journal:  Front Pharmacol       Date:  2013-04-23       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.